This is a phase 1, open label, single-dose, crossover study to investigate the pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine and rosuvastatin in healthy male volunteers.~In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22.~In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22.
This is a phase 1, open label, single-dose, crossover study to investigate the pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine and rosuvastatin in healthy male volunteers~Hypothesis: YHP1604 and telmisartan/amlodipine and rosuvastatin are showing equal pharmacokinetics.